Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

Pheochromocytoma Clinical Trial

Official title:

Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05451134
• Other study ID #: 2022-06
• Status: Active, not recruiting
• Start date: June 30, 2022
• Est. completion date: July 20, 2022

Study information

• Verified date: June 2022
• Source: China National Center for Cardiovascular Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The investigators will retrospectively analyze the clinical data of consecutive patients with pheochromocytomas and paragangliomas admitted between January 2018 and June 2020. The clinical characteristics of patients with and without dysglycemia will be compared, and whether surgery could improve the patients'dysglycemia will be also investigated.

Description:

This retrospective cohort study will include all consecutive adult patients who underwent surgery for PHEOs and catecholamine-secreting PGLs from January 2018 to June 2020. Patients with recurrent PPGLs, those who required steroids after adrenalectomy, and those with inadequate clinical records were excluded. The patients' electronic medical files were reviewed. Patients with dysglycemia included those with diabetes, or impaired fasting glucose, or impaired glucose tolerance. Clinical history data such as age, sex, body mass index (BMI), the presence of preoperative symptoms, biochemical test results, and tumor characteristics, such as tumor diameters and locations were extracted and analyzed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: July 20, 2022
• Est. primary completion date: July 20, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age =18 years old

• patients with surgical pathological diagnosis of pheochromocytomas and paragangliomas(PPGLs)

Exclusion Criteria:

• recurrent PPGLs

• patients who required steroids after adrenalectomy

• patients with inadequate clinical records were excluded.

Related Conditions & MeSH terms

• Paraganglioma
• Pheochromocytoma

Intervention

Other:
• Catecholamines
Focus on whether catecholamine exposure is associated with dysglycemia in patients with pheochromocytoma and paraganglioma

Locations

Country	Name	City	State
China	Xian-Liang Zhou	Beijing	Beijing

Sponsors (2)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases	Peking Union Medical College Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline OGTT(oral glucose tolerance test)results to 6-12 months after surgery	OGTT results (including fasting blood glucose in the text, blood glucose results at 2 hours after oral administration of 75g glucose)at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia	Baseline, 6-12 months after surgery
Secondary	random blood glucose results	random blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia	baseline, 6-12 months after surgery
Secondary	HbA1c	HbA1c results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia	baseline, 6-12 months after surgery
Secondary	fasting blood glucose	fasting blood glucose results at baseline and 6-12 months after surgery will be recorded to assess the effect of surgery on dysglycemia	baseline, 6-12 months after surgery